Brazil is monitoring two patients for possible Ebola infection, a development that has sent a tremor through global markets and prompted the UK to ramp up health checks at major ports of entry. For investors, this is not merely a public health story: it is a reminder that the bond market’s greatest fear is uncertainty, and the ghost of 2014’s West African outbreak has returned to rattle gilt yields.
The Brazilian health ministry confirmed late Thursday that two individuals in São Paulo are under observation after presenting symptoms consistent with the haemorrhagic fever, including high fever and vomiting. Both had recently travelled from Guinea, where a fresh cluster of Ebola cases has been reported. While authorities stress that tests are still pending, the mere possibility has spooked markets. Brazil’s real weakened against the dollar, and the Bovespa index shed 2.3% in early trading before paring losses. The cost of insuring Brazilian sovereign debt against default jumped sharply.
Across the Atlantic, the UK government wasted no time. The Department of Health announced an immediate expansion of health screening at Heathrow, Gatwick, and Manchester airports, with additional staff deployed to monitor passengers arriving from West Africa. Transport Secretary Grant Shapps described the measures as “proportionate and prudent”, but the market saw them as a signal that the worst-case scenario is being priced in.
Let us be clear-eyed about this. The fiscal implications of a major outbreak are not trivial. During the 2014-2016 epidemic, the World Bank estimated that the three worst-affected countries lost $2.2 billion in economic output. For a large emerging economy like Brazil, a full-blown epidemic would hammer tourism, investment, and fiscal revenues. The Brazilian government is already struggling with a primary deficit of 2.1% of GDP; an Ebola crisis would blow that hole wide open, forcing the central bank to choose between printing money or allowing a sovereign debt crisis. Neither option is palatable for holders of Brazilian bonds.
For the UK, the risk is more contained but no less real. Gilt yields fell 8 basis points on the news as investors fled to safety, a classic flight-to-quality move. The pound also weakened. The Treasury will be watching closely: higher border spending and potential quarantine costs could add to the already swollen public spending bill. The Bank of England may have to factor in a pandemic risk premium when setting monetary policy, possibly delaying rate hikes.
Meanwhile, the pharmaceutical companies are the obvious winners of this anxiety. Shares in GlaxoSmithKline and Johnson & Johnson rose modestly on hopes that their experimental Ebola vaccines will be in demand. But for the rest of the market, the warning is clear: the global economy is still fragile, and a new pandemic would be devastating for growth and inflation expectations.
The key metric to watch in the coming days is the volatility index for Brazilian assets, which has already spiked. If the patients test positive, expect a sharp capital flight out of emerging markets and into developed market government bonds. The UK’s border measures may reassure the public, but the market knows that viruses don’t respect borders. Investors should prepare for a prolonged period of uncertainty, and that is never good for the bottom line.
